We are analyzing https://link.springer.com/article/10.1007/bf01211377.

Title:
Interferon and cyclosporin A in the treatment of fulminant viral hepatitis | Journal of Gastroenterology
Description:
The prognosis of fulminant hepatitis due to non-A, non-B virus infection and acute reactivation of hepatitis B virus in HB carriers is generally poor, and the treatment of choice in Western countries is recognized as liver transplantation. In countries such as Japan where liver transplantation is not readily available, however, these intractable types of fulminant hepatitis have to be treated medically. Based on the assumption that persistent replication of causal viruses and enhanced host immune responses, especially cellular immunity, to eradicate the viruses are the key mechanism in progressive liver cell destruction and the poor prognosis, we attempted a combination treatment with interferon and cyclosporin A for these types of fulminant viral hepatitis. Subjects in the present study consisted of 1 patient with acute severe hepatitis without coma and 13 patients with coma (13 with fulminant hepatic failure) due to non-A, non-B virus and acute reactivation of hepatitis B virus. The patients were given interferon-beta, 300 × 104U daily, and cyclosporin A, at an initial dose of 3 mg/kg, with tapering. Fourteen patients with coma received artificial liver support that we devised. The patient with acute severe hepatitis survived, showing histologically remarkable liver regeneration. Eight of the 14 patients with hepatic coma, all of whom were indications for liver transplantation according to the criteria of the King
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

hepatitis, fulminant, virus, google, scholar, liver, article, viral, yoshiba, sekiyama, hepatic, treatment, nona, nonb, reactivation, gastroenterology, cyclosporin, transplantation, failure, med, privacy, cookies, content, journal, interferon, inoue, acute, coma, patients, access, dig, dis, sci, publish, search, prognosis, infection, japan, dna, intern, data, information, log, research, volume, due, combination, subjects, study, patient,

Topics {✒️}

month download article/chapter low-dose methotrexates therapy case report fulminant hepatitis caused privacy choices/manage cookies full article pdf histological liver regeneration european economic area decreased transaminase level cytotoxic drug therapy protein-passing membrane �high performance membranes massive hepatic necrosis fulminant hepatic failure conditions privacy policy fulminant viral hepatitis present study consisted acute severe hepatitis increased liver volume subgenotype a1 hepatitis precore mutant hepatitis accepting optional cookies journal finder publish main content log fulminant hepatitis due related subjects article yoshiba article journal key mechanism check access instant access article log privacy policy personal data choriocarcinoma related 2016 viral hepatitis viral hepatitis books a viral markers liver transplantation article cite fulminant hepatitis optional cookies hepatic coma manage preferences initial dose gerber ma gerin tl dna polymerase hayllar km

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Interferon and cyclosporin A in the treatment of fulminant viral hepatitis
         description:The prognosis of fulminant hepatitis due to non-A, non-B virus infection and acute reactivation of hepatitis B virus in HB carriers is generally poor, and the treatment of choice in Western countries is recognized as liver transplantation. In countries such as Japan where liver transplantation is not readily available, however, these intractable types of fulminant hepatitis have to be treated medically. Based on the assumption that persistent replication of causal viruses and enhanced host immune responses, especially cellular immunity, to eradicate the viruses are the key mechanism in progressive liver cell destruction and the poor prognosis, we attempted a combination treatment with interferon and cyclosporin A for these types of fulminant viral hepatitis. Subjects in the present study consisted of 1 patient with acute severe hepatitis without coma and 13 patients with coma (13 with fulminant hepatic failure) due to non-A, non-B virus and acute reactivation of hepatitis B virus. The patients were given interferon-beta, 300 × 104U daily, and cyclosporin A, at an initial dose of 3 mg/kg, with tapering. Fourteen patients with coma received artificial liver support that we devised. The patient with acute severe hepatitis survived, showing histologically remarkable liver regeneration. Eight of the 14 patients with hepatic coma, all of whom were indications for liver transplantation according to the criteria of the King's College group, survived. Decreased transaminase level, increased liver volume, and histological liver regeneration were observed in all the survivors. The combination of interferon and cyclosporin A is worth attempting in fulminant hepatitis caused by non-A, non-B virus and acute reactivation of hepatitis B virus in HB carriers.
         datePublished:
         dateModified:
         pageStart:67
         pageEnd:73
         sameAs:https://doi.org/10.1007/BF01211377
         keywords:
            fulminant hepatitis
            interferon
            cyclosporin A
            Gastroenterology
            Hepatology
            Abdominal Surgery
            Colorectal Surgery
            Surgical Oncology
         image:
         isPartOf:
            name:Journal of Gastroenterology
            issn:
               1435-5922
               0944-1174
            volumeNumber:30
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Makoto Yoshiba
               affiliation:
                     name:Showa University Fujigaoka Hospital
                     address:
                        name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kazuhiko Sekiyama
               affiliation:
                     name:Showa University Fujigaoka Hospital
                     address:
                        name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kazuaki Inoue
               affiliation:
                     name:Showa University Fujigaoka Hospital
                     address:
                        name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rikiya Fujita
               affiliation:
                     name:Showa University Fujigaoka Hospital
                     address:
                        name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Interferon and cyclosporin A in the treatment of fulminant viral hepatitis
      description:The prognosis of fulminant hepatitis due to non-A, non-B virus infection and acute reactivation of hepatitis B virus in HB carriers is generally poor, and the treatment of choice in Western countries is recognized as liver transplantation. In countries such as Japan where liver transplantation is not readily available, however, these intractable types of fulminant hepatitis have to be treated medically. Based on the assumption that persistent replication of causal viruses and enhanced host immune responses, especially cellular immunity, to eradicate the viruses are the key mechanism in progressive liver cell destruction and the poor prognosis, we attempted a combination treatment with interferon and cyclosporin A for these types of fulminant viral hepatitis. Subjects in the present study consisted of 1 patient with acute severe hepatitis without coma and 13 patients with coma (13 with fulminant hepatic failure) due to non-A, non-B virus and acute reactivation of hepatitis B virus. The patients were given interferon-beta, 300 × 104U daily, and cyclosporin A, at an initial dose of 3 mg/kg, with tapering. Fourteen patients with coma received artificial liver support that we devised. The patient with acute severe hepatitis survived, showing histologically remarkable liver regeneration. Eight of the 14 patients with hepatic coma, all of whom were indications for liver transplantation according to the criteria of the King's College group, survived. Decreased transaminase level, increased liver volume, and histological liver regeneration were observed in all the survivors. The combination of interferon and cyclosporin A is worth attempting in fulminant hepatitis caused by non-A, non-B virus and acute reactivation of hepatitis B virus in HB carriers.
      datePublished:
      dateModified:
      pageStart:67
      pageEnd:73
      sameAs:https://doi.org/10.1007/BF01211377
      keywords:
         fulminant hepatitis
         interferon
         cyclosporin A
         Gastroenterology
         Hepatology
         Abdominal Surgery
         Colorectal Surgery
         Surgical Oncology
      image:
      isPartOf:
         name:Journal of Gastroenterology
         issn:
            1435-5922
            0944-1174
         volumeNumber:30
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Makoto Yoshiba
            affiliation:
                  name:Showa University Fujigaoka Hospital
                  address:
                     name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kazuhiko Sekiyama
            affiliation:
                  name:Showa University Fujigaoka Hospital
                  address:
                     name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kazuaki Inoue
            affiliation:
                  name:Showa University Fujigaoka Hospital
                  address:
                     name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rikiya Fujita
            affiliation:
                  name:Showa University Fujigaoka Hospital
                  address:
                     name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Gastroenterology
      issn:
         1435-5922
         0944-1174
      volumeNumber:30
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Showa University Fujigaoka Hospital
      address:
         name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
         type:PostalAddress
      name:Showa University Fujigaoka Hospital
      address:
         name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
         type:PostalAddress
      name:Showa University Fujigaoka Hospital
      address:
         name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
         type:PostalAddress
      name:Showa University Fujigaoka Hospital
      address:
         name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Makoto Yoshiba
      affiliation:
            name:Showa University Fujigaoka Hospital
            address:
               name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
               type:PostalAddress
            type:Organization
      name:Kazuhiko Sekiyama
      affiliation:
            name:Showa University Fujigaoka Hospital
            address:
               name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
               type:PostalAddress
            type:Organization
      name:Kazuaki Inoue
      affiliation:
            name:Showa University Fujigaoka Hospital
            address:
               name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
               type:PostalAddress
            type:Organization
      name:Rikiya Fujita
      affiliation:
            name:Showa University Fujigaoka Hospital
            address:
               name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
      name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
      name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
      name:Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(57)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.73s.

LINK . SPRINGER . COM {}